Maryland’s Prescription Drug Affordability Board voted unanimously Nov. 16 to approve final regulations setting upper payment limits on Novo Nordisk’s Ozempic and Boehringer Ingelheim’s Jardiance, the first state payment limits on either drug, according to the Baltimore Sun. The limits are projected to save taxpayers $6.1 million a year.
The limits apply to what state and local government purchasers pay for the drugs, not manufacturers’ list prices or what patients pay at the pharmacy counter, so the savings will not necessarily lower patients’ costs, according to the report. The board earlier voted to cap what government plans pay at $274 for a month’s supply of Ozempic and $204 for a 30-day supply of Jardiance. The limits take effect Jan. 1, 2027, with eligible state and local government entities able to participate voluntarily during the first year. Participation becomes mandatory for entities that opt in beginning Jan. 1, 2028.
Drugmakers and industry groups argued during public comment that the limits could disrupt access, increase utilization management and create reimbursement problems for pharmacies and providers. Community Access National Network warned the limits could pressure community pharmacies, particularly independent ones, because government purchasers could pay pharmacies less even if the pharmacies pay the same prices to wholesalers and manufacturers.
PhRMA said Maryland should focus on insurer and pharmacy benefit manager practices that drive patients’ costs and that “medicines may not be available if a pharmacy, hospital or physician cannot purchase them at the capped price,” according to the report. Andrew York, the board’s executive director, said the regulations include safeguards to prevent supply chain disruptions and that the board will evaluate post-implementation data on utilization management and pharmacy friction.
Colorado set the first state upper payment limit on any drug in 2025, a $600 cap on a 50-milligram dose of Enbrel, but a federal judge preliminarily blocked it in July on patent preemption grounds, leaving Maryland’s limits as the first likely to take effect. Maryland created its board in 2019, becoming the first state to establish one.